Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$81.36 USD
-1.01 (-1.23%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $81.64 +0.28 (0.34%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Ligand Pharmaceuticals Incorporated [LGND]
Reports for Purchase
Showing records 301 - 320 ( 718 total )
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Kyprolis Beats; Recent and Anticipated Label Expansions Represent Revenue Inflection Points
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Promacta Beats and OmniAb Franchise Continues to Grow; Target Nudged Up to $170
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Kyprolis Planting Flags for Second-Line Multiple Myeloma and Eyeing Front-Line
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Clucking Away; New OmniAb Deal Includes First Agreement With OmniChicken
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
New Year, More Milestones as OmniAb Chugs Along
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Numbers Look Even Brighter Now With New Tax Law; Target Upped to $169
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Viking Nails It Providing Further Pipeline Value; Target Bumped up to $163
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
As Einstein Said, "Insanity Is Doing the Same Thing Over and Over Again and Expecting Different Results"
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Analyst Day Recap; Numbers Growing in All Categories
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J